Socius exercises investment rights
(Thomson Reuters ONE) -
Leiden, The Netherlands, December 6, 2010. Pharming Group NV ("Pharming" or
"the Company") (NYSE Euronext: PHARM) today announced that Socius CG II, Ltd, a
subsidiary of Socius Capital Group, LLC ("Socius"), based in New York and Los
Angeles, following Pharming's call for the ?12 million loan notes, as announced
last Friday, exercised their investment rights under the ? 16.1 million
investment agreement with Pharming .
As announced last Friday, under these investment rights, Pharming will issue
75,849,057 shares to Socius, In addition to these shares, Socius is entitled to
24,339,623 warrants with an exercise price of ?0.212 (21.2 cents). The shares
will be delivered and admitted to listing and trading on Euronext Amsterdam
following the publication of a prospectus (expected within the next two weeks),
Socius can either place the shares acquired by it in the market or accumulate
them up to a maximum holding in Pharming of 21.8% of the number of outstanding
shares. Socius is committed not to short sell or enter into any hedging
transactions related to Pharming shares.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of unmet
medical needs. Ruconest(TM) (Rhucin® in non-European territories) is a
recombinant human C1 inhibitor approved for the treatment of angioedema attacks
in patients with HAE in all 27 EU countries plus Norway, Iceland and
Liechtenstein. The product is also under development for follow-on indications,
i.e. antibody-mediated rejection (AMR) and delayed graft function (DGF)
following kidney transplantation. The advanced technologies of the Company
include innovative platforms for the production of protein therapeutics,
technology and processes for the purification and formulation of these products.
Additional information is available on the Pharming website,www.pharming.com.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact:
Marjolein van Helmond, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54 or
E:m.helmond(at)pharming.com
Press release (PDF):
http://hugin.info/132866/R/1469099/406440.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE
[HUG#1469099]
Unternehmensinformation / Kurzprofil:
Datum: 06.12.2010 - 08:00 Uhr
Sprache: Deutsch
News-ID 49411
Anzahl Zeichen: 3238
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 350 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Socius exercises investment rights"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
